Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Impact Advisors Receives Best in KLAS #1 Overall IT Services Firm Alongside Three Additional Best in KLAS Awards


News Image

“We are truly honored by the ongoing support of our clients. Receiving Best Overall IT Services Firm alongside three additional Best in KLAS awards validates we have maintained our excellence in the IT realm while also exceeding client expectations with our newer, expanded capabilities.”

Impact Advisors, a leading healthcare management consulting firm, has been named Best in KLAS #1 Overall IT Services Firm and #1 Best in KLAS for Security & Privacy Consulting Services, ERP Implementation Leadership, and Financial Improvement Consulting in the “2023 Best in KLAS: Software and Services Report”.

The firm has earned 28 KLAS distinctions over the last sixteen years, which is more than double other service providers. This is the sixth time Impact Advisors has received Best in KLAS Overall IT Services Firm, the third consecutive year the firm has received Best in KLAS Security & Privacy Consulting Services, and the first award for Best in KLAS ERP Implementation Leadership and Best in KLAS Financial Improvement Consulting. “We are truly honored by the ongoing support of our clients.

Receiving Best Overall IT Services Firm alongside three additional Best in KLAS awards validates we have maintained our excellence in the IT realm while also exceeding client expectations with our newer, expanded capabilities,” said Andy Smith, managing partner and co-founder of Impact Advisors. “We’ve been able to achieve these results because our associates are leading experts in the industry who are delivering high-quality services to help our clients take care of their patients and communities.

”The Best in KLAS report recognizes software and services companies that excel in helping healthcare professionals improve patient care. All rankings are a direct result of the feedback of thousands of providers over the last year. A Best in KLAS award signifies to the healthcare IT industry the commitment and partnership that the top vendors should provide. Companies are ranked across several categories, including loyalty, operations, relationships, services, and value.

A CIO shared thoughts on working with Impact Advisors in June 2022, “My first call is always to Impact Advisors. Due to the leadership and culture of their company, Impact Advisors exceeds my expectations. I look for a firm I can absolutely trust, so it is huge for me to know that I can trust Impact Advisors. The executive involvement is very appropriate. I can call the firm, and if there is any issue, it will be dealt with very easily. I know that in any workstream, the quality will be high.

”Ranked #1 Best Overall IT Services Firm

The Overall IT Services Firm ranking is reserved for those firms that have a minimum of three separate IT services that are ranked or newly rated in four separate market segments. Impact Advisors received a score of 92.3 for Overall IT Services Firm.

Ranked #1 for Security & Privacy Consulting Services

The Best in KLAS Security & Privacy Consulting Services designation is awarded to firms who help organizations assess, enhance, and develop security and privacy programs through technical or advisory work, which should result in a more secure and private environment. Services include security risk assessment, HIPAA privacy assessment, virtual/interim CISO, and penetration, vulnerability, network web application, and security testing. Impact Advisors received a score of 99.5 for Security & Privacy Consulting Services. Ranked #1 for ERP Implementation Leadership

The Best in KLAS ERP Implementation Leadership designation is reserved for firms that are engaged in overall implementation and provide project managers and/or technical staff for ERP projects. The firm must demonstrate at least two of the three following key competencies: business transformation, application implementation management, and technical expertise. Services usually span the implementation life cycle, including implementation planning, change management, project management, system build/integration and end-user training. Firms are expected to have consultants with both depth and breadth of experience.

Impact Advisors received a score of 96.6 for ERP Implementation Leadership.

Ranked #1 for Financial Improvement Consulting

The Best in KLAS Financial Improvement Consulting is awarded to firms focused on improving the financial performance of a healthcare organization, which could include reducing cost, increasing net revenue, and/or improving efficiency. Engagements often assist with redesigning the revenue cycle of the organization, are very large in scope and investment (i.e., exceed a minimum of $500K), and are over six months in duration.

Impact Advisors received a score of 94.4 for Financial Improvement Consulting.16 Consecutive Years of KLAS Recognition“

Our mission is to create a positive impact for our clients and these recognitions demonstrate that our team is succeeding in upholding those values,” said Pete Smith, managing partner and co-founder of Impact Advisors. “We strive to create a top-notch culture within the firm and are thrilled to be celebrating 16 years of receiving accolades from KLAS in both new and repeated award categories.” Over the last 16 years, Impact Advisors has received 28 KLAS Research recognitions including:·

Best Overall IT Services Firm (2012, 2013, 2014, 2015/2016, 2019, 2023)

· Best in KLAS: Security & Privacy Consulting Services (2021, 2022, 2023)

· Best in KLAS: ERP Implementation Leadership (2023)

· Best in KLAS: Financial Improvement Consulting (2023)

· Best in KLAS: HIT Implementation Leadership – Large (2018, 2019, 2020)

· Best in KLAS: IT Advisory Services (2015/2016)

· Best in KLAS: Clinical Implementation – Principal (2011, 2012, 2013, 2014)

· Best in KLAS: Planning and Assessment (2008, 2009, 2010, 2012)

· Best in KLAS: HIE Consulting (2012)

· Category Leader Award: Clinical Optimization (2017, 2018, 2019)

· Category Leader Award: Revenue Cycle Optimization (2018)

Impact Advisors will attend the Best in KLAS Awards Ceremony on April 17th.

About Impact Advisors

Impact Advisors is a leading healthcare management consulting firm committed to solving the industry’s emerging and evolving challenges. Our high-performing team of clinical, financial, operations and technology experts collaborate to architect quality solutions and deliver measurable value for our clients. We are the most awarded consulting firm in healthcare, with services recognized among Best in KLAS® for 16 consecutive years and a culture designated “Best Place to Work” by Modern Healthcare for 13 years. To learn more about our service quality and innovative culture, visit http://www.impact-advisors.com.###

Virsys12 Announces Record Revenue and Releases New Product


Virsys12 logo

We are proud to meet the needs of healthcare providers and payers as we work towards the mutual goal of transforming healthcare.

Virsys12, a leading Salesforce solution integrator in the healthcare industry and AppExchange ISV, today announced doubled revenue in 2022 and its new product, V12 Network Plus.

V12 Network Plus, a lighter entry product, is designed for healthcare payers and providers to experience automated provider network and data management with a lower price point and faster implementation.

“We are proud to meet the needs of healthcare providers and payers as we work towards the mutual goal of transforming healthcare,” said CEO and Founder Tammy Hawes. “Our technology products, V12 Network Pro and V12 PDE provide industry leading provider network management functionality for payers and providers. With the addition of V12 Network Plus, we are meeting customers where they are in their automation journey and at a lower price point for provider data management and provider network management automation.”

Virsys12 was founded in 2011 with the mission of transforming the business of healthcare through technology. It fulfills its mission by providing consulting services and software applications that help healthcare organizations run their operations more efficiently and effectively – ensuring that patients, members, providers and payers have a positive experience.

The company has grown rapidly since receiving funding from Salesforce Ventures’ SI Trailblazers Fund in 2018, becoming one of Nashville’s 25 largest women-owned businesses. Virsys12 also doubled its revenue in 2021 and 2022.

“It is so fulfilling to see Virsys12 on this trajectory, said Vice President of Sales & Solutioning Clint Mooneyham. “Our space is very competitive, both from a professional services and SaaS-based application landscape. I believe we are poised to continue to disrupt our space and that the best days are still ahead.”

In addition to its revenue growth, Virsys12 also grew its employee count from 22 to 47 and promoted two new C-Suite members — Seth Hobgood as chief technology officer, Justin Poggioli as chief services officer and hired Michael Gardner as chief strategy officer and Brandon Marsee as chief financial officer.

“V12 Network and its turnkey integrations have transformed provider and payer workloads and will continue to evolve and enhance them further,” said Chief Technology Officer Seth Hobgood. “With both industry-leading provider data partners, like CAQH and ProviderTrust, and our own AI-driven provider data reconciliation tool, V12 PDE, the future of Virsys12 and provider data governance is exciting.”

The company’s signature product, V12 Network, was first listed on Salesforce AppExchange in 2014 as a tool to help Accountable Care Organization​s​ better build and manage networks of healthcare providers. The product has since expanded to help other healthcare organizations – including payers and health plans, specialty networks, integrated clinical networks, third party administrators and benefit managers – build and manage provider networks. Recently, it was included in Gartner’s “Market Guide for U.S. Healthcare Payers’ Provider Network Management Applications” and one of seven U.S. healthcare technology companies named as a ‘Contender’ in the “IDC MarketScape: U.S. Provider Data Management for Payers 2022 Vendor Assessment.”

About Virsys12

Virsys12 is a healthcare technology firm transforming the business of healthcare with innovative products and solutions for provider lifecycle and Salesforce’s Digital 360 initiative, which brings together key components to help companies transform customer engagement in the all-digital, work-from-anywhere world. Founded in 2011, Virsys12 provides both applications and services to ensure customer success. It partners with healthcare organizations of all sizes to help them create an optimized experience for their members, patients, providers and partners that produces better outcomes and lowers costs. To learn more, visit http://www.virsys12.com.

Share article on social media or email:

Shine United Takes Health Care Marketing Campaign to the “Masterpiece” Level


News Image

“The ‘Masterpieces’ campaign is disruptive in the health care market’s approach to storytelling. The stories we created aren’t about charts, facts, and figures,” said Samantha Smith, managing partner and executive creative director at Shine United.

Inspired by the uplifting and unique patient journey, as well as ongoing innovation in health care, Shine United, an agency known for creating forward-thinking solutions for its clients, is excited to announce the launch of its “Masterpieces” campaign for UW Health.

Taking a different approach to marketing within the health care industry, Shine’s creative team focused on the patient experience. Leaning into extensive patient research acknowledging what patients most desire from their health care providers — to be seen, heard, and recognized as individuals — Shine was able to bring to life UW Health’s vision and philosophy, literally showing all patients as the beautiful works of art they are. By using bold, out-of-the-box narratives, sleek design elements, customized music, and energetic color palettes, the campaign emphasizes the complexities of being human. It’s a representation of patients’ hopes and goals for their health, with a layered artistic appeal. “Masterpieces” creatively speaks to the individualized quality of care, empowerment, and comprehensive treatments UW Health provides.

“So much of health care marketing looks, feels and sounds the same: heroic doctors, flashy technology, cliché patient portrayals. It seems easy to lose sight of the ‘why.’ But that one-size-fits-all mentality has expired. The patients — their unique backgrounds and future ambitions — are what it’s all about,” said Samantha Smith, managing partner and executive creative director at Shine United. “The ‘Masterpieces’ campaign is disruptive in the health care market’s approach to storytelling. We set out to prove that UW Health champions a different approach to health care innovation — one entirely inspired by patients. The stories we created aren’t about charts, facts, and figures. They highlight humans as complex beings, with multifaceted lives that need to be understood as part of the health care journey. By honoring that every single human is a masterpiece with their own story, we took UW Health’s commitment to personalized care to the next level.”

To learn more about what Shine United can offer your brand, connect with us here or via LinkedIn, Instagram, Facebook, or Twitter. You can see the initial creative for the ongoing UW Health campaign here.

About Shine United

Shine United is a $51 million independent advertising, design, and digital agency located in America’s Heartland — Madison, Wisconsin. Best known for its innovative brand positioning and creative firepower, Shine has been tapped by such brands as Harley-Davidson, Mizuno Running, Discover Card, Amazon, Kohler, Festival Foods, Toppers Pizza, Winston Fly Rods, Carver Yachts, and UW Health. Shine was named one of the best small agencies in the country by One. A Magazine, and one of the best places to work in the country by Outside Magazine. Shine’s work has been featured in Communication Arts, Print, Graphis, Ad Age, and The New York Times.

Share article on social media or email:



CHA Hollywood Presbyterian Medical Center Ranked No. 2 in California for Coronary Interventional by Healthgrades


News Image

CHA Hollywood Presbyterian Medical Center (CHA HPMC), a member of CHA Health Systems, a global network providing a full spectrum of dynamic healthcare services, has been ranked as the second best hospital in California for coronary interventional procedures, according to a new analysis released by Healthgrades, the leading online resource that connects consumers, physicians, and health systems. Additionally, CHA HPMC has been recognized as one of America’s 100 Best Hospitals for Coronary Intervention for two years in a row (2022-2023), America’s 100 Best for Spine Surgery for three years in a row (2021-2023), and a recipient of Orthopedic Surgery Excellence Award (2023).

“We are honored to achieve this recognition which is a reflection of the expertise of our multidisciplinary care team, our best practices and protocols, and our never-ending commitment to providing optimal care and a high quality patient experience.” said Jamie Yoo, Chief Executive Officer at CHA HPMC. “Patients seek CHA HPMC for our track record and reputation in delivering high caliber healthcare services that they have come trust for almost a century.”

Percutaneous coronary intervention is a minimally invasive, non-surgical procedure used to treat blockages in the coronary (heart) arteries and improve blood flow to the heart. CHA HPMC is designated a STEMI Receiving Center by the Los Angeles County Emergency Medical Services which means its entire cardiac care team – starting from the Emergency Department – has the training and expertise to recognize and address heart conditions, and is ready to treat heart attack patients 24 hours a day, 365 days a year. Furthermore, CHA HPMC’s new patient tower, opening in 2024, will have expanded emergency department and advanced operating rooms and surgical services to offer cutting-edge care and speedy recovery for patients.

Hospitals ranked among the top in the state by Healthgrades are recognized for providing patients with superior clinical outcomes in coronary intervention procedures, including angioplasty with stent. For the state ranking analysis, Healthgrades evaluated clinical performance for nearly 4,500 hospitals nationwide focusing on 18 key specialties across a mix of chronic, urgent, and surgical areas.

About CHA Hollywood Presbyterian Medical Center

CHA Hollywood Presbyterian Medical Center (CHA HPMC) is a nationally recognized acute care facility that has cared for Hollywood and its surrounding communities since 1924. Today, CHA HPMC offers comprehensive health care services with a 469-bed acute care facility, including 89 skilled nursing beds. The hospital has a medical staff of more than 550 physicians and specialists, representing 69 specialties and 75 different countries. CHA HPMC embraces the area’s diverse, multicultural patient populations by providing all who walk through its doors quality care in a compassionate manner. It is a member of CHA Health Systems, a dynamic global healthcare organization that provides a full spectrum of services in seven countries around the world, including 86 hospitals and clinics, 30 research and 14 education institutions and 31 bio/pharmaceutical/healthcare companies. For more information about CHA HPMC, visit http://www.hollywoodpresbyterian.com.

Share article on social media or email:

NACDS Statement in Response to State of the Union Address


NACDS President and CEO Steven C. Anderson issued the following statements on Tuesday night in relation to President Biden’s State of the Union Address:

On the future of patients’ access to pharmacy services:

“While we all want to move on from COVID-19, doing so should not mean leaving behind millions of Americans who have relied on their trusted, local pharmacies for testing, vaccinations, and care during the pandemic. America’s pharmacies serve as a healthcare lifeline, particularly for rural and historically-excluded communities, and the Administration and Congress should work with pharmacies to ensure continued access and service to those who need it most.”

On patients’ access to prescription medications:

“America’s pharmacies applaud the bipartisan commitment to provide patients with access to more affordable medicines, and we urge the President and Congress to go further by stopping the manipulation by pharmacy benefit manager (PBM) middlemen that is increasing patients’ medication costs, limiting patients’ choice of pharmacies, and restricting access to medicines that are right for them. Pharmaceutical benefit manipulation can no longer be tolerated, and policymakers should demand accountability, transparency, and fairness in how PBMs operate and impact patients and the pharmacy teams who serve them.”

Share article on social media or email:

Spine Surgeon Introduces Novel Method for Treating Chronic Back and Neck Pain


LIFT: Meditations to Boost Back Health is a new series of instructional meditations created by spinal and orthopedic surgeon, Ken Hansraj, MD, to improve spine health, help lessen chronic neck and back pain, and provide an alternative to surgery and medication.

Ken Hansraj, MD, the Spine Surgeon who brought international attention to the global health problem of “Text Neck,” introduces LIFT: Meditations to Boost Back Health, a new series of instructional meditations created to improve spine health, help lessen chronic neck and back pain, and provide an alternative to surgery and medication.

Countless people around the world are suffering with chronic neck and back pain and the treatment is costing the global economy an estimated billions of dollars each year. In addition, the current opioid crisis in the U.S. has many looking for an alternative to medication for relief of chronic pain. Research and clinical application support that meditation can significantly reduce pain. LIFT: Meditations to Boost Back Health were designed by a medical physician to help in pain management and to provide the tools to protect the spine and improve wellbeing.

“As a spinal surgeon, I have spent my life treating chronic pain. I have seen many people sometimes suffer needlessly because of improper posture, poor habits, and mind-set,” said Dr. Hansraj. “Chronic pain, especially back pain, can negatively impact a person’s quality of life, but there are alternatives to medication. I have seen first-hand the profound effects of meditation and it inspired me to create the LIFT meditation program to help the many people around the world afflicted with neck and back pain.”

LIFT: Meditations to Boost Back Health is a six-part program developed and led by Dr. Hansraj to help improve neck and spine health, shift focus, and provide an alternative therapy to surgery and medication.

Through each LIFT meditation, Dr. Hansraj takes listeners on a journey through various scenarios of directed thoughts and suggestions to lead the imagination toward a relaxed, focused state to help cleanse physical and emotional burdens. The LIFT guided meditations are designed to help listeners become better in tuned with their bodies and to better recognize everyday postural forces that can cause back and neck pain. Throughout the program, Dr. Hansraj teaches techniques to release tension and pain and help listeners improve wellbeing.

“I believe in whole-body wellness, preventative care, and treating the spine as the principal indicator of general health,” said Dr. Hansraj. “As part of a holistic approach, I recommend meditation to my patients as a supplemental therapy.”

LIFT: Meditations to Boost Back Health was produced by Greg Knowles, James Fallon, and Joe Costable at the award-winning Bimperl Studio. Grammy award winner Darlene Koldenhoven and Juilliard professors Kendall Durelle Briggs, Emi Ferguson and Forrest Gore rendered the beautiful supporting music.

LIFT is available on Spotify, Apple Music, Amazon, iTunes, Pandora, Deezer, and can be sampled at DrKen.HearNow.com

ABOUT Dr. Ken Hansraj

Ken Hansraj, MD, creator of LIFT: Meditations to Boost Back Health and author of WATCH YOUR BACK, is a spinal and orthopedic surgeon with more than 20 years’ experience specializing in preventative medicine and using minimally invasive approaches to spinal care when possible. Well known for his ground-breaking work on “text neck,” he has appeared on CNN, CBS, FOX, NBC, ABC, and NPR. He was named one of America’s most compassionate doctors in 2020 by Vitals, and lives with his wife and son in Rockland County, New York. To learn more, visit drken.us.

LIFT – Meditations to Boost Back Health | By Ken Hansraj, MD | Produced by Greg Knowles and James Fallon | Music Performed by: Darlene Koldenhoven, Emi Ferguson and Kendall Durelle Briggs | Forrest Gore | ISBN 1-882320-06-0 | Copyright 2023 BlackPatent, LLC

Share article on social media or email:

Paul Harkness takes the helm as President for ESCO Agency


ESCO, the early pioneer and the longstanding leader of loss and damage coverage for hearing aids, announces a leadership change. With nearly three decades of hearing industry experience, Harkness steps in to lead ESCO as President. Known for his vast network of relationships within hearing healthcare, ENT, and medical practices across the US, Paul will leverage his experience to guide ESCO through the next phases of growth and development.

After leading teams for several top hearing aid manufacturers, Harkness moved to the business solutions arena, where he led Amplifon’s Elite Hearing Network’s strong membership and revenue growth over 8+ years. He later joined the specialized leadership team at AuDConnex, with its unique recipe of best practice sharing. Most recently, Harkness was the CEO of Lantos Technologies, a 3D ear scanner manufacturer, based in Derry, NH, which focused on modernizing and elevating the patient experience. With a reputation as a team, culture, and business builder at heart, Harkness comments,” I am honored to work with ESCO’s experienced management team and dedicated staff. Together, we are poised to take ESCO to the next level of growth, innovation, and success.” Paul studied business at Metropolitan State University in St. Paul, Minnesota, where he grew up. Currently, he resides in Minneapolis with his family.

About ESCO

Since 1989, ESCO has provided comprehensive loss, damage, and repair protection for hearing aids. As an advocate, ESCO partners with hearing care professionals to protect and make the best use of a hearing aid wearer’s investment in better hearing.

ESCO provides protection against the unexpected financial burden of a sudden loss and options to help hearing aid wearer maximize their investment after the original manufacturer warranty has ended.

As the largest independent provider of hearing aid insurance; ESCO’s place in the industry is to offer more than just financial security, ESCO works to inform, educate, and help provide lasting peace of mind for their policyholders.

Share article on social media or email:

Allotrope Foundation Further Expands Access to Interoperable Laboratory Data Standards with Public JSON-based Analytical Data Models


Allotrope Foundation Logo

By making Allotrope Simple Model (ASM) available to the public, Allotrope Foundation seeks to enable wide-spread data standardization throughout the scientific community through adoption of this technology.

Allotrope Foundation, an international consortium of chemical & life sciences organizations, is excited to announce the public release of its extensive set of standardized data models that cover over forty different techniques and domains essential to research and development in the analytical laboratory. The data models leverage the modern JavaScript object notation (JSON) format, which is widely used as the backbone of communications for today’s internet and immediately familiar to any software engineer or data scientist. The Allotrope Simple Models (ASMs) are designed by thought leaders in Allotrope’s diverse community of industry, governmental, and academic institutions to represent a true pan-industry data standard to streamline analytical data processing and accelerate digital transformation in the lab. Designed to be implemented quickly and easily, ASM models capture critical results and parameters essential to accurately capture, preserve, and transfer laboratory data. These models are specifically tailored to meet the exponential growth in the use of bedrock analytical data to fuel artificial intelligence and machine learning techniques and cover diverse techniques such as NMR spectroscopy, chromatography, and mass spectrometry.

The models leverage Allotrope’s standardized, open formal vocabulary of terms and definitions commonly used in scientific data and experiments, the Allotrope Foundation Ontologies (AFO). By employing these standardized terms and the widely adopted text-based JSON format, the ASM family of models represents an easy entry point in the journey towards digital laboratory and data standardization, serving as a steppingstone towards a future implementation which fully leverages Allotrope Foundation’s more information-rich semantic-based standardization technology. Through the application of reusable modeling patterns, the Allotrope data models make laboratory data interoperable and reusable anywhere ASM is used.

As with the Allotrope Foundation Ontologies, the Allotrope Simple Models will be available for immediate usage by any for- or non-profit institution under a variety of Creative Commons licenses. The licensing is designed to provide flexibility for use tailored to specific needs while maintaining a singular, common standard developed by the Allotrope community.

“We’re incredibly excited to make the work of our community broadly available to all. A standard needs to both represent diverse viewpoints and be widely adopted to see long-lasting value” said Corey Bakalarski, Chairman of Allotrope Foundation. “Through Allotrope’s wide community of data producers and consumers, we’ve been able to create standards that will work for all, and we hope that today’s announcement that Allotrope Simple Models are free to use will make it easy for everyone to adopt ready-made data standards into their work – and free up their time to focus on more complex and critical tasks.”

Allotrope Foundation’s suite of standardization tools for the digital laboratory reduces instrument integration costs, eliminates manual data transcription, and drives democratization of data for AI/ML modeling of product & process development, which revolutionizes the way that laboratory professionals and scientists work. By building upon a semantically-enabled framework, Allotrope’s systems work together to allow easy adoption of standards using common file formats that are quick to integrate but provide a powerful way to consistently represent data in a diverse array of domains. To keep pace with the rapidly changing world of research and development, Allotrope data models are readily extensible to additional content via the Allotrope community in the future.

“ASM allows IFPEN to retrieve and centralize its lab data across a wide range of analytical techniques, allowing our public institution to comply with its open-data requirements, and researchers both internally and externally to advance scientific progress, leveraging the power of big data” said Maxime Visconte, Industrial and lab IT manager at IFP Energies Nouvelles, the French public research and innovation organization in the field of energy.

By making ASM available to the public, Allotrope Foundation seeks to enable wide-spread data standardization throughout the scientific community through adoption of this technology. For more information on how to access the ASM and licensing terms, please visit the Allotrope Foundation website at https://www.allotrope.org/asm.

About Allotrope Foundation:

Allotrope Foundation is a consortium of chemical & life sciences companies formed in 2013 to revolutionize the way we acquire, share and gain insights from scientific data through the application of community-derived data standards consistently delivered via an extensible technology framework. For more information, please visit http://www.allotrope.org.

Share article on social media or email:

Latest Information about Medication Safety in Breastmilk Now Easily Accessible via New LactRx App


LactRx Logo

The LactRx app expands ease of access to this critical information for providers and the public worldwide.

The non-profit Organization of Teratology Information Specialists (OTIS), through its public-facing service known as MotherToBaby, launches LactRx, a free app providing current information on the use of medications, vaccines, diagnostic agents & drugs of misuse during breastfeeding. The LactRx app provides easy access to the LactMed database, a resource from the National Library of Medicine (NLM).

In 2019 the NLM announced that the LactMed app was being discontinued. The announcement prompted a discussion between Phil Anderson, PharmD, FASHP, UC San Diego clinical professor and author of LactMed and Christina Chambers, PhD, MPH, MotherToBaby Past President and Mommy’s Milk: Human Milk Biorepository Program Director, about MotherToBaby sponsoring a new app for LactMed. “This was a hugely popular resource with millions of hits,” said Chambers. Because of this, she saw it as an opportunity for MotherToBaby to help build and host a new app with all of the LactMed information.

In October of 2021, the idea was brought to the leadership of the Organization of Teratology Information Specialists (OTIS), the professional non-profit that provides the MotherToBaby no-cost service. Development commenced and LactRx was born.

“The NLM made the decision to continue supporting web access to LactMed, and to discontinue support for its app. However, in Dr. Anderson’s experience, the app was a very popular and a user-friendly mode of access to the data,” explained Chambers. “In collaboration with NLM, MotherToBaby was given permission to create the LactRx app and, thus, to expand ease of access to this critical information for providers and the public worldwide.”

To download LactRx, please click:

iPhone

Android

Information presented in the LactRx app is not intended to be a substitute for professional judgment. Users should consult personal healthcare providers for breastfeeding advice related to their particular situation.

MotherToBaby also works closely with the NLM to contribute bilingual (English/Spanish) evidence-based fact sheets regarding medications, vaccines, diseases, herbal supplements, occupational exposures and more during pregnancy and breastfeeding.

MotherToBaby traditionally provides information on exposures before and during a pregnancy as well as breastfeeding through its no-cost helpline 866-626-6847, texting service 855-999-3525 and website http://www.MotherToBaby.org, where the public can live chat or e-mail an expert.

More about OTIS and MotherToBaby

The Organization of Teratology Information Specialists (OTIS) is a professional scientific society made up of individuals engaged in assessing and evaluating risks to pregnancy and breastfeeding from environmental exposures. Members include, but are not limited to, specialists in the fields of obstetrics and gynecology, pediatrics, genetics, dysmorphology, perinatal epidemiology, teratology, behavioral teratology, pharmacy, genetic counseling, nursing, midwifery, maternal and child health, public health, and includes experts that provide MotherToBaby services and researchers that conduct MotherToBaby Pregnancy Studies. MotherToBaby is a suggested resource by many federal agencies including the Centers for Disease Control and Prevention (CDC). MotherToBaby is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents of this release are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the U.S. Government. To learn more about MotherToBaby and OTIS, please visit http://www.MotherToBaby.org.

Share article on social media or email:

Celebrating Rare Disease Day and 40 Years of the Orphan Drug Act Advocating for Rare Disease Patients and Their Families


Figure: A collage of selected art4rare submissions from 2021 and 2022

Our vision is to accelerate research and development of diagnostics and therapeutics through education, advocacy, training, research, digital patient engagement, new technology platforms for registries, clinical trials, and investments

Global life expectancy has more than doubled over the last two centuries, from less than 30 years to more than 72 years.(1) Despite the advances during the ‘golden age of medicine’ throughout the first half of the 20th century, for persons living with rare diseases, 26% still die before the age of five, and depending on the severity of the disease, 37% have a reduced life expectancy.(2) Pharmaceutical companies were historically loathe to research and develop life-saving drugs and treatments for rare diseases because it wasn’t profitable marketing drugs to such a small segment of the population. Rare disease patients became known as ‘orphans,’ having been abandoned by prescription drug manufacturers.(3) In 1983, the U.S. Congress passed the Orphan Drug Act to incentivize drug manufacturers to pursue the development of drug treatments for rare diseases. Dr. Harsha Rajasimha is the Founder and Executive Chairman of the Indo-US Organization for Rare Diseases (IndoUSrare), a not-for-profit organization that seeks to bridge the gap between the western and eastern hemispheres when it comes to orphan diseases. He notes, “It has been 40 years since this watershed moment in the research and development of treatments for rare diseases. While we celebrate our significant progress, we must continue to look toward the still foggy road ahead.”

The FDA’s Orphan Drug Act describes a rare disease as a medical condition that affects less than 200,000 people in the United States. There are currently over 10,000 rare diseases that impact more than 30 million people nationwide. For 40 years, the FDA has worked with patients, patient advocates, and researchers, encouraging the development of safe and effective drugs, biologics, and treatment products for orphan diseases.(4) When the FDA grants an orphan drug designation, sponsors and developers can receive research grants, tax credits for clinical trials, and a potential seven years of market exclusivity. To the latter, Congress determined the benefits of increased access to new treatments for rare disease patients, countervail granting drug sponsors a monopoly of an approved orphan drug.(5)

The U.S. Department of Health and Human Services (DHHS) reports that the passage of the Orphan Drug Act has ‘unquestionably stimulated’ the development of orphan drugs.(5) From 1983 to 2019, the FDA conferred 5,099 drugs and biologics orphan drug designation. The top three orphan drug designations include oncology (1,910 | 37%), neurology (674 | 13%), and infectious diseases (436 | 9%). The proportion of designations for pediatric-onset diseases has increased to 27% from 2010 to 2020.(6) Clinical trials have become more patient-centric by incorporating electronic patient-reported outcomes, patient advocacy groups, and nonprofit organizations dedicated to driving policy and advancements in the treatment of rare disease patients.

Frank Sasinowski, MS, MPH, JD, Director at Hyman Phelps McNamara P.C., and Founding board member of IndoUSrare says, “One in 10 persons in every community around the globe are afflicted by 1 of the 10,000 rare diseases that exist. Forty years ago, almost no one was trying to develop treatments for any rare disease. Now there are over 1,080 orphan therapies for over 500 rare diseases. Progress is being made all over the world as people with rare diseases come together to share their medical stories in registries that accelerate the development of new therapies.”

“For all of this progress,” Dr. Rajasimha observes, “approximately 93% of orphan diseases remain without any FDA-approved drugs. In countries such as India, the Drug Controller General of India (DCGI) may waive the need for additional clinical trials for already FDA-approved orphan drugs. At present, there are more than 1,200 active clinical trials recruiting patients for gene therapies; five cell/gene therapies have been approved by the FDA so far, and this number is expected to grow tenfold over the next decade, which means we could see hundreds and even thousands of genetic diseases having new treatments in our lifetime.”

IndoUSrare focuses on accelerating therapies for rare diseases by building collaborative bridges between the U.S. and the Indian subcontinent for education, advocacy, and research. Dr. Rajasimha adds, “Our vision is to accelerate research and development of diagnostics and therapeutics through education, advocacy, training, research, digital patient engagement, new technology platforms for registries, clinical trials, and investments.”

February is Rare Disease Month, and February 28, 2023, is International Rare Disease Day. Its mission is to raise awareness and bring about change for over 300 million people living with rare diseases across the globe, as well as their families and caregivers. Rare Disease Day features special talks by key opinion leaders, panel discussions, and lived experience accounts from patients living with rare diseases worldwide. Started in 2008, Rare Disease Day is patient-led and includes contributions from individuals, families, caregivers, healthcare professionals, researchers, clinicians, policymakers, and industry representatives.

Dr. Rajasimha explains, “Rare Disease Month gives patients and their families a voice. Too many may never see or benefit from future breakthroughs in treatment for their own condition in their lifetime. Their advocacy is pure and full of compassion for the millions who are suffering worldwide. The orphan disease R&D community also has an ideal opportunity during Rare Disease Month to share their progress, amplify their message, and urge continued progress globally. We need rare disease advocacy and registries to become global villages with a reach beyond the United States and Europe to Asia, Africa, and Latin America. South Asia, including the Indian subcontinent, is densely populated, with a quarter of the world’s population living there. It’s critical for those in the rare disease community dedicated to advancing education, research, encouraging policy enhancements, and improving treatments and quality of life for those living with a rare disease to come together and make themselves heard.”

IndoUSrare will be hosting a fireside chat with a legend this Rare Disease Day and distributing awards for the ongoing Art4Rare and Science4Rare contests that will conclude on Feb 21, 2023.

About IndoUSrare

IndoUSrare is a humanitarian nonprofit 501(c)(3) tax-exempt public charity organization based in the United States. Founder and Chairman Dr. Harsha Rajasimha, who lost a child to a rare disease in 2012, has been a rare disease advocate for more than 10 years. To address the unmet needs of diverse patients with rare diseases globally, the leadership team comprised of experienced professionals from research, advocacy, regulatory, and drug development seeks to build cross-border collaborations connecting stakeholders of rare diseases in low- and middle-income regions such as India, with their counterparts and clinical researchers in the United States to improve the diversity of clinical trial participants, accelerate research and development, and improve equitable access to life-saving therapies to diverse populations of rare disease patients. Visit https://indousrare.org.

References: 

1. Roser, M., Ortiz-Ospina, E., & Ritchie, H. (2013). Life Expectancy. Our World in Data. ourworldindata.org/life-expectancy#:~:text=Globally%20the%20life%20expectancy%20increased

2. Rare Diseases & Critical Care. (n.d.). Home. aop-health.com/global_en/rare-diseases#:~:text=Many%20rare%20diseases%20are%20life%2Dthreatening%20or%20very%20burdensome&text=About%2026%25%20of%20the%20patients

3. Research, C. for D. E. and. (2019). Orphan Products: Hope for People With Rare Diseases. FDA. fda.gov/drugs/information-consumers-and-patients-drugs/orphan-products-hope-people-rare-diseases

4. Commissioner, O. of the. (2020, February 20). Rare Diseases at FDA. FDA. fda.gov/patients/rare-diseases-fda

5. OFFICE OF INSPECTOR GENERAL THE ORPHAN DRUG ACT IMPLEMENTATION AND IMPACT. (2001). oig.hhs.gov/oei/reports/oei-09-00-00380.pdf

6. Miller, K. L., Fermaglich, L. J., & Maynard, J. (2021). Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet Journal of Rare Diseases, 16. doi.org/10.1186/s13023-021-01901-6